drugset / Trial / NCT05568550
Pembro With Radiation With or Without Olaparib
RandomizedParallel-groupOpen-labelTreatment
Summary
This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in men with high-risk localized prostate cancer.
Timeline
- Start
- 2023-07-27
- Primary completion
- 2027-12-02
- Completion
- 2029-07-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 200 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |